Major depressive disorder according to DSM-5 Healthy volunteers
Conditions
Interventions
Group 1: 20 SAD patients
study medication: N-3 PUFA, specifically: eicosapentaenoic acid (EPA) 1.5g and docosahexaenoic acid (DHA) 0.5g per day as capsules as oral treatment for 8 weeks
Group 2: 20 SAD patients
study medication: placebo capsules as oral treatment for 8 weeks
Group 3: 20 healthy controls
study medication: N-3 PUFA, specifically: eicosapentaenoic acid (EPA) 1.5g and docosahexaenoic acid (DHA) 0.5g per day as capsules as oral treatment for 8 weeks
Group 4: 20 healthy controls
study medication: placebo capsules as oral treatment for 8 weeks
Sponsors
Medizinische Universität Wien
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for SAD patients 1. Age 20 to 55 years; 2. DSM-5 diagnosis of recurrent major depressive disorder with current depressive episode with seasonal pattern specifier (current seasonal depressive episode) established by diagnostic interview according to the SCID; 3. Global Seasonality Score = 10 on the Seasonal Pattern Assessment Questionnaire (SPAQ); 4. SIGH-SAD score of =20 at screening visit; 5. Somatic health based on history, physical examination, ECG, and laboratory screening; 6. No treatment of SAD in the last 6 months (especially antidepressants and light therapy); 7. Willingness and competence to complete the informed consent process. Inclusion criteria for healthy controls (matching regarding age and sex with SAD) 1. Age 20 to 55 years; 2. Somatic and psychiatric health based on history, physical examination, ECG, laboratory screening, SCID; 3. Willingness and competence to complete the informed consent process.
Exclusion criteria
Exclusion criteria: Exclusion criteria for SAD and HC 1. Present psychiatric disorders; 2. Suicidal ideations (corresponding to a score of =3 on the SIGH-SAD); 3. Major (unstable) medical or neurological illness; 4. Disallowed concomitant medication (see chapter 5.4) during the last 6 months; 5. Intake of nutritional supplements containing n-3 PUFA; 6. Bright light therapy (as antidepressant treatment) within the last 6 months; 7. Current substance abuse including alcohol, drugs of abuse, or any medication in a manner which is indicative of substance-related disorders (e.g. substance dependency) according to the DSM-5; 8. Failure to comply with the study protocol or follow the instructions of the investigators; 9. Positive urine pregnancy test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whole brain functional connectivity (measured by fMRI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin-6, tumor nekrosis factor alpha | — |
Countries
Austria
Contacts
Public ContactDietmar Winkler
Medizinische Universität Wien
Outcome results
None listed